ACME UNITED CORPORATION Initiates Class II Recall for BZK Antiseptic Towelettes Due to CGMP Deviations
ACME UNITED CORPORATION has initiated a Class II recall for Dynarex BZK Antiseptic Towelettes (Benzalkonium Chloride 0.13%) due to Current Good Manufacturing Practice (CGMP) deviations. This nationwide U.S. recall, D-0376-2026, impacts product safety and supply chain integrity. Procurement and regulatory teams must assess exposure and re-evaluate supplier qualification for Benzalkonium Chloride-based products to mitigate disruption and ensure compliance.
FDA Mandates Class II Recall for ACME UNITED's BZK Antiseptic Towelettes Over CGMP Failures
ACME UNITED CORPORATION, headquartered at 1 Waterview Dr Ste 200, Shelton, CT 06484-4368, has initiated a Class II voluntary recall, designated D-0376-2026, for its Dynarex BZK Antiseptic Towelettes. This critical action, commenced on January 20, 2026, stems directly from identified Current Good Manufacturing Practice (CGMP) deviations. The affected product, specifically Dynarex, BZK Antiseptic Towelettes (Benzalkonium Chloride 0.13%), 5x7, 1000 packets, with NDC 67777-245-04, was manufactured for Dynarex Corporation, located at 10 Glenshaw Street, Orangeburg, NY 10962, USA. The recall encompasses Lot numbers 53518 and 53519, both bearing an expiration date of June 2027. For procurement directors and regulatory affairs heads, this signifies an immediate need to halt distribution and quarantine affected inventory. CGMP deviations, even for an Over-The-Counter (OTC) drug like Benzalkonium Chloride, indicate fundamental lapses in quality control, potentially compromising product safety, efficacy, and purity. This directly impacts patient trust and carries significant commercial and reputational risks. Business development executives must recognize that such regulatory actions can erode market confidence and necessitate proactive communication with downstream partners and customers to manage potential liabilities and maintain brand integrity in the competitive antiseptic market.
Product Profile and Market Reach of Affected Benzalkonium Chloride Antiseptics
The recalled product, Dynarex BZK Antiseptic Towelettes, contains Benzalkonium Chloride 0.13%, a widely used quaternary ammonium compound functioning as an antiseptic. These towelettes are classified as a Human OTC Drug, intended for topical application, and are a staple in healthcare settings, first aid kits, and consumer markets for skin antisepsis. The product's broad utility means its recall has far-reaching implications across various sectors. The distribution pattern for these specific lots (53518, 53519) is nationwide within the United States, indicating a significant market penetration. For supply chain VPs, this nationwide reach translates to a complex logistical challenge in identifying, retrieving, and managing the return of affected units. The product's NDC 67777-245-04, along with related package NDCs such as 67777-245-01, 67777-245-11, and others, provides specific identifiers for inventory management and recall execution. The recall's Class II classification suggests that while the probability of serious adverse health consequences is remote, temporary or medically reversible adverse health consequences are possible. This necessitates prompt action from all entities involved in the supply chain to protect public health and minimize commercial exposure.
Supply Chain Exposure: Mitigating Disruption for Benzalkonium Chloride Products
The nationwide distribution of ACME UNITED CORPORATION's Dynarex BZK Antiseptic Towelettes (Benzalkonium Chloride 0.13%) means that a broad spectrum of healthcare providers, pharmacies, distributors, and retailers across the United States are directly exposed to this Class II recall. Procurement directors must immediately identify all inventory of Lot numbers 53518 and 53519 within their supply chains, initiate quarantine procedures, and coordinate returns with ACME UNITED CORPORATION. Failure to promptly remove affected products not only risks regulatory non-compliance but also potential liability should adverse events occur. For businesses relying on these specific towelettes for their operations, such as hospitals, clinics, or emergency services, this recall necessitates an urgent re-evaluation of current stock and the rapid identification of alternative sources to maintain continuity of care and service. The widespread use of Benzalkonium Chloride as an antiseptic means that even a single product recall can create ripple effects, prompting increased scrutiny on all BZK-containing products. Supply chain VPs should leverage this event to stress-test their supplier qualification processes and diversify their procurement strategies for critical OTC drug components and finished products, especially those with broad market distribution.
Strategic Sourcing: Identifying Alternative Benzalkonium Chloride Suppliers
Given the recall of Dynarex BZK Antiseptic Towelettes, procurement teams must proactively identify and qualify alternative suppliers for Benzalkonium Chloride-based antiseptic products. While specific alternative suppliers are not detailed in our current intelligence for this particular event, the market for Benzalkonium Chloride is robust, with numerous manufacturers globally. Key considerations for procurement directors include evaluating suppliers based on their FDA compliance history, manufacturing capabilities, quality management systems, and supply chain resilience. Companies like Becton, Dickinson and Company (BD), 3M, and Cardinal Health offer a range of antiseptic products, though specific Benzalkonium Chloride towelettes from these firms would require direct verification of their product portfolios and regulatory standing. Qualification timelines for new suppliers can range from 6 to 18 months, depending on the complexity of the product and the stringency of internal validation processes. Therefore, initiating this due diligence immediately is paramount. Business development executives should also explore partnerships with suppliers demonstrating robust quality control and a strong regulatory track record to minimize future supply chain vulnerabilities and ensure uninterrupted product availability, thereby safeguarding market share and customer relationships.
Broader Regulatory Landscape: Implications of CGMP Deviations Across the Industry
While specific prior regulatory actions against ACME UNITED CORPORATION are not detailed in our intelligence, this Class II recall due to CGMP deviations aligns with a discernible trend of heightened FDA scrutiny on manufacturing quality across the chemical and life sciences industry. Recent parallel events underscore this regulatory emphasis: for instance, Essential Wellness Pharma faced a Class II recall for Progesterone Injection due to sterility assurance failures in June 2026, and Spectra Medical Devices encountered a similar Class II recall for Lidocaine HCl Injection for sterility deficiencies. Guardian Drug Co. Inc. also experienced multiple Class II recalls for Tums and HyVee Antacids due to metallic contamination in June 2026. These events collectively signal that the FDA is actively enforcing CGMP standards, particularly concerning product purity, sterility, and overall manufacturing control. For regulatory affairs heads, this means that any identified CGMP deviation, regardless of product type, can trigger significant regulatory action, including recalls, import alerts, or Warning Letters. Companies must ensure their quality systems are not only compliant but also demonstrably robust, with continuous monitoring and proactive remediation strategies in place to avoid becoming part of this growing list of regulatory actions. This trend emphasizes the critical need for continuous investment in quality infrastructure and personnel.
Remediation Pathway and Future Outlook for ACME UNITED CORPORATION
The Class II recall for Dynarex BZK Antiseptic Towelettes remains 'Ongoing,' indicating that ACME UNITED CORPORATION is actively engaged in the recall process, which includes notifying customers, retrieving affected product, and investigating the root cause of the CGMP deviations. For the company, the immediate priority is to ensure the complete and effective removal of all affected lots (53518, 53519) from the market. Concurrently, ACME UNITED CORPORATION must conduct a thorough investigation into the specific CGMP failures that led to this recall. This typically involves a comprehensive audit of their manufacturing processes, quality control procedures, and facility operations to identify systemic issues. Remediation will require implementing corrective and preventive actions (CAPA) to address these deviations, which may include process revalidation, equipment upgrades, or enhanced personnel training. The FDA will closely monitor these remediation efforts, and a successful resolution will depend on the company's ability to demonstrate sustainable compliance. Failure to adequately address the underlying CGMP issues could lead to further regulatory actions, such as an official Warning Letter, increased inspections, or even an injunction, severely impacting the company's ability to market and distribute its products in the U.S. Business development executives should prepare for potential long-term impacts on brand reputation and market access, necessitating transparent communication and robust quality commitments to regain stakeholder trust.